Adaptimmune ‘besieged’ with suitors following its MM data report
By Nuala Moran
Monday, December 9, 2013
Adaptimmune Ltd. released positive data from the ongoing open-label Phase I/II trial of its autologous T-cell immunotherapy in treating multiple myeloma, reporting a 77 percent complete response rate in the 20 patients treated to date, at 100 days post-infusion of the modified cells. The results, presented yesterday at the American Society of Hematology (ASH) meeting in New Orleans have brought potential partners flocking to Adaptimmune’s door, according to CEO James Noble. "We are pretty much besieged at the moment,” he told BioWorld Today. Oxford, UK-based Adaptimmune’s optimistic news was matched by data from several studies of CTL019, also a modified T-cell immunotherapy, which is owned by Novartis AG.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.